Wells Fargo & Company MN Boosts Stake in Codexis, Inc. (CDXS)

Wells Fargo & Company MN lifted its holdings in Codexis, Inc. (NASDAQ:CDXS) by 227.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 390,797 shares of the biotechnology company’s stock after buying an additional 271,503 shares during the period. Wells Fargo & Company MN’s holdings in Codexis were worth $2,599,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Baillie Gifford & Co. increased its holdings in shares of Codexis by 1.1% in the 3rd quarter. Baillie Gifford & Co. now owns 1,478,097 shares of the biotechnology company’s stock worth $9,830,000 after buying an additional 16,684 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Codexis by 7.4% in the 2nd quarter. California State Teachers Retirement System now owns 72,298 shares of the biotechnology company’s stock worth $394,000 after buying an additional 5,000 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Codexis by 30.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,264 shares of the biotechnology company’s stock worth $192,000 after buying an additional 8,244 shares during the last quarter. State Street Corp increased its holdings in shares of Codexis by 26.8% in the 2nd quarter. State Street Corp now owns 580,623 shares of the biotechnology company’s stock worth $3,168,000 after buying an additional 122,757 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in shares of Codexis in the 2nd quarter worth about $1,499,000. Hedge funds and other institutional investors own 65.71% of the company’s stock.

Codexis, Inc. (CDXS) opened at $9.00 on Friday. Codexis, Inc. has a 52 week low of $3.60 and a 52 week high of $9.45.

A number of research firms have recently weighed in on CDXS. BidaskClub upgraded shares of Codexis from a “hold” rating to a “buy” rating in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $8.50 target price on shares of Codexis in a report on Tuesday, November 21st. Jefferies Group boosted their target price on shares of Codexis from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, October 13th. Finally, Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $7.81.

TRADEMARK VIOLATION WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.com-unik.info/2018/01/14/wells-fargo-company-mn-boosts-stake-in-codexis-inc-cdxs.html.

Codexis Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit